Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 10/20 | 0.74 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.74 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.74 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.74 |
| ▸ | GART | P22102 | 6/20 | 0.74 |
| ▸ | DHFR | P00374 | 4/20 | 0.74 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.74 |
| ▸ | ATIC | P31939 | 2/20 | 0.74 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.74 |
| ▸ | FRK | P42685 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14523040 | 0.91 | TYMS (0.63) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL15061080 | 0.90 | TYMS (0.62) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL16661582 | 0.90 | TYMS (0.62) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL13998236 | 0.89 | TYMS (0.75) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL13814356 | 0.88 | TYMS (0.74) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL12370807 | 0.88 | GART (0.59) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL18659339 | 0.87 | TYMS (0.78) | TYMSFOLR1SLC46A1SLC19A1GART | |
| SCHEMBL13181213 | 0.87 | TYMS (0.78) | TYMSFOLR1SLC46A1SLC19A1GART | |
| Pemetrexed SCHEMBL7144918 | 0.85 | GART (1.00) | TYMSFOLR1SLC46A1SLC19A1GART | |
| Pemetrexed SCHEMBL5959741 | 0.85 | GART (1.00) | TYMSFOLR1SLC46A1SLC19A1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-14 | — | — | US | disclosed |
| US-9650384-B2 | Substituted pyrimidine compounds and methods of use and manufacture | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-02-11 | — | — | US | disclosed |
| EP-2104501-B1 | METHODS OF CANCER TREATMENT WITH IGF1R INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8362245-B2 | Processes for preparing intermediates of pemetrexed | SICOR INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2032989-B1 | IGFBP2 BIOMARKER | SCHERING CORP (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | SICOR INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263851-A1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | DPYD, TYMP, TYMS | TYMS 3/4885FOLR1 48/4885SLC46A1 181/4885 |
| US-20170260190-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE | DHFR, FOLR1, DPYD | TYMS 4/4885FOLR1 2/4885SLC46A1 22/4885 |
| US-20160039830-A1 | Substituted Pyrimidine Compounds and Methods of Use and Manufacture | DHFR, FOLR1, DPYD | TYMS 4/4885FOLR1 2/4885SLC46A1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.